EA201000497A1 - Противомалярийная фармацевтическая композиция - Google Patents

Противомалярийная фармацевтическая композиция

Info

Publication number
EA201000497A1
EA201000497A1 EA201000497A EA201000497A EA201000497A1 EA 201000497 A1 EA201000497 A1 EA 201000497A1 EA 201000497 A EA201000497 A EA 201000497A EA 201000497 A EA201000497 A EA 201000497A EA 201000497 A1 EA201000497 A1 EA 201000497A1
Authority
EA
Eurasian Patent Office
Prior art keywords
malary
pharmaceutical composition
delivery
proposed
malaria
Prior art date
Application number
EA201000497A
Other languages
English (en)
Other versions
EA017804B1 (ru
Inventor
Клайв Булс
Калвин Росс
Мартин Самс
Original Assignee
Протофарма Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Протофарма Лимитед filed Critical Протофарма Лимитед
Publication of EA201000497A1 publication Critical patent/EA201000497A1/ru
Publication of EA017804B1 publication Critical patent/EA017804B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/22—Valves or arrangement of valves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Согласно изобретению предложены фармацевтические композиции для лечения и профилактики малярии, содержащие артеметер и триглицерид с цепью средней длины, изготовленные для трансмукозальной сублингвальной, трансбуккальной или назальной доставки, в особенности посредством распыления. Кроме того, предложены устройства для доставки, содержащие данные композиции.
EA201000497A 2007-10-25 2008-10-27 Противомалярийная фармацевтическая композиция EA017804B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0720967.9A GB0720967D0 (en) 2007-10-25 2007-10-25 Anti-material pharmaceutical composition
GBGB0806510.4A GB0806510D0 (en) 2007-10-25 2008-04-10 Anti-malarial pharmaceutical composition
PCT/GB2008/050999 WO2009053758A1 (en) 2007-10-25 2008-10-27 Anti-malarial pharmaceutical composition

Publications (2)

Publication Number Publication Date
EA201000497A1 true EA201000497A1 (ru) 2010-12-30
EA017804B1 EA017804B1 (ru) 2013-03-29

Family

ID=38829944

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201000497A EA017804B1 (ru) 2007-10-25 2008-10-27 Противомалярийная фармацевтическая композиция
EA201300151A EA026281B1 (ru) 2007-10-25 2008-10-27 Способ лечения или предупреждения малярии

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201300151A EA026281B1 (ru) 2007-10-25 2008-10-27 Способ лечения или предупреждения малярии

Country Status (26)

Country Link
US (5) US20110015260A1 (ru)
EP (3) EP2749267A1 (ru)
JP (2) JP5438018B2 (ru)
CN (2) CN103622950B (ru)
AP (2) AP3542A (ru)
AU (1) AU2008315767B2 (ru)
BR (2) BR122013005952A2 (ru)
CA (1) CA2702506C (ru)
CY (1) CY1116759T1 (ru)
DK (1) DK2209464T3 (ru)
EA (2) EA017804B1 (ru)
ES (2) ES2494340T3 (ru)
GB (3) GB0720967D0 (ru)
HK (1) HK1190645A1 (ru)
HR (1) HRP20140773T1 (ru)
MX (1) MX2010004392A (ru)
MY (2) MY161745A (ru)
NZ (1) NZ584672A (ru)
PE (1) PE20091322A1 (ru)
PH (2) PH12010500880A1 (ru)
PL (1) PL2209464T3 (ru)
PT (1) PT2209464E (ru)
RS (1) RS53507B1 (ru)
SI (1) SI2209464T1 (ru)
WO (1) WO2009053758A1 (ru)
ZA (1) ZA201002607B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140256761A1 (en) * 2009-04-22 2014-09-11 Robert Lewis Steele Enhanced artemisinin-based combination therapy for treating parasitic mediated disease
GB2469791B (en) * 2009-04-23 2011-12-14 Londonpharma Ltd Transmucosal formulation of compounds providing dihydroartemesinin for use in the treatment of neoplastic disease
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
US20120058158A1 (en) * 2009-04-23 2012-03-08 Londonpharma Ltd. Sublingual Pharmaceutical Composition Comprising a Neutral Oil
US8290525B2 (en) 2010-01-15 2012-10-16 Comcast Cable Communications, Llc Text alternative to established voice call session
US8481757B2 (en) * 2010-02-04 2013-07-09 Georgua Tech Research Corporation Compounds and compositions useful in the treatment of malaria
US20140256762A1 (en) * 2012-07-06 2014-09-11 Robert Lewis Steele Artemisinin-based combination therapy for treating viral mediated disease
TWI733649B (zh) * 2014-03-07 2021-07-21 巴哈馬商克利普頓集團公司 用於治療寄生蟲介導疾病之強化的基於青蒿素組合療法
GB201414918D0 (en) * 2014-08-21 2014-10-08 Corbitt Terence Simon Formulations for transmucosal delivery
GB201414919D0 (en) * 2014-08-21 2014-10-08 Corbitt Terence Simon Formulations for transmucosal delivery
US20170326102A1 (en) * 2014-11-27 2017-11-16 Cipla Limited Pharmaceutical Composition Comprising an Artemisinin Derivative for Nasal or Pulmonary Delivery
US20220280734A1 (en) * 2021-03-07 2022-09-08 Sultan A. M. Daham Intaking an antiviral by inhalation or spraying for respiratory tract infection

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4869899A (en) * 1986-03-10 1989-09-26 Walter Burghart Pharmaceutical preparation and process for producing the same
US5057501A (en) * 1990-03-13 1991-10-15 Dermatologic Research Corporation Methods for treatment of papulosquamous and eczematous diseases
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
US5578637A (en) * 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
US20030082107A1 (en) * 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
CH692321A5 (de) * 1997-11-03 2002-05-15 Mepha Ag Pharmazeutisch wirksame Zusammensetzung, welche eine gegen Malariaparasiten wirksame Substanz enthält.
RU2129809C1 (ru) * 1998-04-24 1999-05-10 Захарчук Анатолий Васильевич Способ получения пищевого продукта в капсулах
CN1084333C (zh) * 1998-06-17 2002-05-08 中国科学院上海药物研究所 新的青蒿素化合物,其制备方法以及含有它们的药物组合物
SI1095042T1 (sl) * 1998-07-14 2006-04-30 Bayer Healthcare Ag Antiparazitski artemizininski derivati
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2153786B1 (es) * 1999-06-10 2001-10-16 S A L V A T Lab Sa Composicion farmaceutica liquida para la administracion oral de principios activos amargos y susceptibles de hidrolisis.
FR2796276B1 (fr) * 1999-07-15 2003-05-16 Oreal Composition sous forme solide comprenant une huile et un compose gelifiant particulier, procede de traitement cosmetique et utilisation dudit compose
US6617356B2 (en) * 2000-01-03 2003-09-09 Naturally Scientific Inc Gel system for oral and topical administration of water insoluble and/or water intolerant drugs and supplements
JP3752127B2 (ja) * 2000-03-21 2006-03-08 花王株式会社 油脂組成物
JP2003534356A (ja) * 2000-06-02 2003-11-18 フォーブス メディ−テック インコーポレーテッド 短鎖、中鎖及び長鎖トリグリセリドから成る油組成物及び体重増加を減少させるためのその使用。
US20040038933A1 (en) * 2000-10-20 2004-02-26 Yutaro Kaneko Pharmaceutical compositions, dose and method for treating malaria
US6951846B2 (en) * 2002-03-07 2005-10-04 The United States Of America As Represented By The Secretary Of The Army Artemisinins with improved stability and bioavailability for therapeutic drug development and application
SI1575569T1 (sl) * 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
JP2004307428A (ja) * 2003-04-10 2004-11-04 Porien Project Kk 原虫感染症予防治療薬
US20050042281A1 (en) * 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
WO2006009825A1 (en) * 2004-06-17 2006-01-26 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
CN1650854A (zh) * 2004-12-08 2005-08-10 广州中生生物技术有限公司 一种含有蒿甲醚（或蒿乙醚或蒿琥酯）微乳剂的制备工艺
US20060233895A1 (en) * 2005-04-15 2006-10-19 Brown Paul R Herbal remedy for treating Lyme disease
EP1879583A2 (en) * 2005-05-03 2008-01-23 Mutual Pharmaceutical Company, Inc. Quinine formulations
ATE544444T1 (de) * 2005-10-11 2012-02-15 Yissum Res Dev Co Zusammensetzungen für die nasale abgabe
EP2641595A1 (en) * 2006-01-25 2013-09-25 Insys Therapeutics, Inc. Sublingual fentanyl spray
CN101310720A (zh) * 2007-05-22 2008-11-26 天津丹溪国药研究所 一种治疗疟疾的蒿甲醚滴丸剂的制备方法
CN101317839A (zh) * 2007-06-05 2008-12-10 天津丹溪国药研究所 一种治疗疟疾的复方蒿甲醚滴丸剂的制备方法
BRPI1014887A8 (pt) * 2009-04-23 2019-02-12 Londonpharma Ltd composição farmacêutica para uso no tratamento de neoplasias e uso de um composto provendo di-hidroartemesinina via dosagem sublingual, transmucosal, bucal ou nasal
US20120058158A1 (en) * 2009-04-23 2012-03-08 Londonpharma Ltd. Sublingual Pharmaceutical Composition Comprising a Neutral Oil
GB2481728B (en) * 2010-06-30 2012-05-23 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids

Also Published As

Publication number Publication date
US20140179772A1 (en) 2014-06-26
ES2540727T3 (es) 2015-07-13
GB0720967D0 (en) 2007-12-05
BRPI0817833A2 (pt) 2015-03-31
CN103622950A (zh) 2014-03-12
BR122013005952A2 (pt) 2015-07-14
EP2653153A1 (en) 2013-10-23
PH12013501567A1 (en) 2014-10-08
EP2209464B1 (en) 2014-06-04
HRP20140773T1 (hr) 2014-11-07
US20180071207A1 (en) 2018-03-15
JP2011500781A (ja) 2011-01-06
AP2013006997A0 (en) 2013-07-31
CN103622950B (zh) 2016-05-04
EA017804B1 (ru) 2013-03-29
ES2494340T3 (es) 2014-09-15
JP2014088400A (ja) 2014-05-15
CA2702506C (en) 2015-08-25
PT2209464E (pt) 2014-09-05
GB0819559D0 (en) 2008-12-03
JP5438018B2 (ja) 2014-03-12
MY153119A (en) 2014-12-31
US20190290576A1 (en) 2019-09-26
DK2209464T3 (da) 2014-08-25
MX2010004392A (es) 2010-06-25
HK1190645A1 (zh) 2014-07-11
CA2702506A1 (en) 2009-04-30
EP2653153B1 (en) 2015-05-27
EP2209464A1 (en) 2010-07-28
PH12010500880A1 (ru) 2014-10-07
MY161745A (en) 2017-05-15
AU2008315767B2 (en) 2013-11-07
US20160038404A1 (en) 2016-02-11
CY1116759T1 (el) 2017-03-15
EA026281B1 (ru) 2017-03-31
SI2209464T1 (sl) 2014-11-28
US20110015260A1 (en) 2011-01-20
AU2008315767A1 (en) 2009-04-30
WO2009053758A1 (en) 2009-04-30
GB0806510D0 (en) 2008-05-14
AP2010005231A0 (en) 2010-04-30
AP3542A (en) 2016-01-13
BRPI0817833A8 (pt) 2015-09-15
PE20091322A1 (es) 2009-10-04
CN101835464B (zh) 2013-05-15
EA201300151A1 (ru) 2013-10-30
CN101835464A (zh) 2010-09-15
RS53507B1 (en) 2015-02-27
GB2454567A (en) 2009-05-13
NZ584672A (en) 2012-03-30
GB2454567B (en) 2010-06-30
PL2209464T3 (pl) 2014-11-28
AP2920A (en) 2014-05-31
PH12013501567B1 (en) 2014-10-08
ZA201002607B (en) 2011-10-26
EP2749267A1 (en) 2014-07-02

Similar Documents

Publication Publication Date Title
EA201000497A1 (ru) Противомалярийная фармацевтическая композиция
MY164646A (en) Nicotine lozenge compositions
WO2007143674A3 (en) Methods for buccal, lingual or sublingual dosing regimens of epinephrine for the treatment of allergic emergencies
IL195030A (en) IV dpp inhibitor assemblies
DE602007012559D1 (de) H die schleimhaut
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA200800415A1 (ru) Удаление пероксида из носителя для доставки лекарственного средства
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
DK2395979T3 (da) Orale doseringssammensætninger med forsinket frigivelse, der indeholder amorft ccdo-me
NO20090175L (no) Stabile laquinimod sammensetninger
CL2008000896A1 (es) Composicion que mantiene el cuidado bucal periodico que comprende un aminoacido basico; uso en el tratamiento terapeutico de la superficie bucal.
UA108636C2 (xx) Пептид
GB2461659A (en) Structured compositions comprising a clay
EA201170567A1 (ru) Смесь силанов
ZA200708834B (en) Compositions for oral transmucosal delivery of metformin
CL2007002812A1 (es) Compuestos derivados de quinolina; composicion farmaceutica, utiles para inhibir el vih.
MY153391A (en) Composition for controlling parasites on animals
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
FR2923834B1 (fr) Nouvelles compositions polysicocyanates hydrodispersibles.
DK1985303T3 (da) Oral sammensætning indeholdende interferon-alpha
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
MX2011010961A (es) Formula en aspersion sublingual que comprende dihidroartemesinina.
BR112012000596A2 (pt) processo e composições farmacêuticas para o tratamento de hiperglicemia pós-prandial de diabetes tipo ii por via transmucosa bucal
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU